Navigation Links
Endo Pharmaceuticals and BioDelivery Sciences International Sign Licensing Agreement for BEMA Buprenorphine

CHADDS FORD, Pa., Jan. 6, 2012 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today it has signed a worldwide license and development agreement with U.S.-based BioDelivery Sciences International (Nasdaq: BDSI) for BEMA Buprenorphine.

BEMA Buprenorphine is a transmucosal form of buprenorphine, a partial mu-opiate receptor agonist, which incorporates a bioerodible mucoadhesive (BEMA) technology. BEMA Buprenorphine is currently in phase III trials for the treatment of moderate to severe chronic pain.  

Financial terms of the agreement include an upfront payment of $30 million to BioDelivery Sciences International, royalties of net sales, and up to approximately $150 million in milestones contingent upon achievement of pre-defined, late state clinical and regulatory events and achievement of certain sales targets.

"Endo is committed to serving as an integrated solutions provider for the development and commercialization of products focused on the management of pain," said Dave Holveck, president and chief executive officer of Endo Pharmaceuticals. "The addition of BEMA Buprenorphine will broaden Endo's portfolio of pain therapeutics, allowing us to offer an integrated suite of products that currently include Opana ER, Voltaren Gel and Lidoderm, as well as a broad range of generic pain products. We look forward to working closely with BDSI on the development of this important asset." 

About Endo
Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company with a diversified business model, operating in three key business segments – branded pharmaceuticals, generics and devices and services.  We deliver an innovative suite of complementary products and services to meet the needs of patients in areas such as pain management, pelvic health, urology, endocrinology and oncology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries American Medical Systems and Qualitest Pharmaceuticals, as well as its affilate HealthTronics, Inc., please visit

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements.  Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine
2. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
3. Acella Pharmaceuticals, LLC Announces Its Acquisition of the PRENATE® Family of Trademarks and Associated Intellectual Property
4. Syndax Pharmaceuticals Signs Agreement with Ventana Medical Systems, Inc. to Develop Companion Diagnostic Test for Entinostat
5. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
6. Arena Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
7. Inovio Pharmaceuticals to Present at Biotech Showcase Investor Conference
8. MDA Awards $1 Million to Tivorsan Pharmaceuticals for Accelerating Pivotal Pre-Clinical Work on TVN-102 as a Potential Muscular Dystrophy Treatment
9. Lotus Pharmaceuticals Announces Business Reorganization and Provides Updates on the Beijing Headquarters Building
10. Lexicon Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
11. Omthera Pharmaceuticals, Inc. to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... "Radioimmunoassay Market by Type (Reagents & ... Academics, Clinical Diagnostic Labs), Application (Research, Clinical ... 2020" report to their offering. ... addition of the "Radioimmunoassay Market by ...
(Date:11/25/2015)...  The total global healthcare industry is expected to grow ... Latin America has the highest projected growth at ... Japan ), is second with growth projected at 11.5%. ... healthcare expenditure. In 2013-2014, total government funded healthcare was nearly ... to 41.2% in 2013-2014. In real terms, out of pocket ...
(Date:11/25/2015)... 25, 2015  Linden Care, LLC, a retail specialty ... for patients suffering from chronic pain, said today that ... Restraining Order (TRO) enjoining Express Scripts from unilaterally terminating ... --> --> The company ... legal options. --> --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that ... ). More than 3.7 billion people under the age of 50 – or 67% ... WHO's first global estimates of HSV-1 infection . , "The data shocks us highly!" ...
(Date:11/27/2015)... ... , ... A simply groundbreaking television series, "Voices in America", which is hosted ... array of issues that are presently affecting Americans. Dedicated to providing the world with ... changing the subjects consumers focus on, one episode at a time. , In ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to ... Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored ... one of twelve colleges and universities in the state of California make the cut. ...
(Date:11/27/2015)... ... November 27, 2015 , ... Avid collector, Andrew Hawley ... Michigan boxing style concert posters. This is one of Joplin's most famous and beautiful ... at the University of Michigan in Ann Arbor. The According to Hawley, "It is ...
(Date:11/26/2015)... NV (PRWEB) , ... November 26, 2015 , ... Inevitably ... strategy. Many customers choose to buy during the Black Friday and Cyber Monday ... Shoppers don’t need to search the Internet high and low to find the best ...
Breaking Medicine News(10 mins):